Literature DB >> 6618641

Responses of the stenosed and contralateral kidneys to [Sar1, Thr8] AII in human renovascular hypertension.

S C Textor, A Novick, S K Mujais, R Ross, E L Bravo, F M Fouad, R C Tarazi.   

Abstract

To better define the intrarenal hemodynamic effects of angiotensin in human renovascular hypertension, 10 patients underwent renal hemodynamic and functional measurements before and during infusion of a competitive angiotensin analog, [Sar1, Thr8] AII. Eight had technically satisfactory split function studies. Despite a fall in mean arterial pressure (132 +/- 6 to 121 +/- 6 mm Hg, p less than 0.05) and humoral changes consistent with angiotensin-mediated hypertension, the intrarenal effects of this analog were commonly those of an angiotensin agonist, producing vasoconstriction and sodium retention. This was quantitatively greatest in the contralateral kidney, whose preinfusion sodium excretion (86 +/- 30 microEq/min vs 25 +/- 9 microEq/min, p less than 0.02) and glomerular filtration rate (76 +/- 7 ml/min vs 41 +/- 7 ml/min, p less than 0.01) were higher than the stenotic kidney. In some cases, an increase in renal blood flow and rise in sodium excretion were evident during angiotensin blockade, suggesting a tonic intrarenal action of angiotensin. Although renin vein renin values differed markedly between the stenotic and contralateral kidney (ratio = 2.05 +/- 0.30), relative changes in effective renal plasma flow were correlated (r = 0.84: p less than 0.01) during infusion of this analog. These results underscore the differences in sensitivities between vascular beds to the effects of angiotensin II and the major role of the contralateral kidney in renal function and sodium homeostasis in human renovascular hypertension.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6618641     DOI: 10.1161/01.hyp.5.5.796

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  3 in total

Review 1.  ACE inhibitors in renovascular hypertension.

Authors:  S C Textor
Journal:  Cardiovasc Drugs Ther       Date:  1990-02       Impact factor: 3.727

2.  Current opinions in renovascular hypertension.

Authors:  Ankit N Mehta; Andrew Fenves
Journal:  Proc (Bayl Univ Med Cent)       Date:  2010-07

Review 3.  An update on renovascular hypertension.

Authors:  Martin Senitko; Andrew Z Fenves
Journal:  Curr Cardiol Rep       Date:  2005-11       Impact factor: 2.931

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.